Fresenius Medical Care AG (VIE:FME)
Austria · Delayed Price · Currency is EUR | Market Cap | 9.73B -27.4% |
| Revenue (ttm) | 19.43B -0.5% |
| Net Income | 937.78M +42.9% |
| EPS | 3.34 +50.0% |
| Shares Out | n/a |
| PE Ratio | 10.38 |
| Forward PE | 9.15 |
| Dividend | 1.49 (4.09%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | n/a |
| Open | 36.34 |
| Previous Close | 40.31 |
| Day's Range | 36.34 - 36.68 |
| 52-Week Range | 34.69 - 47.78 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial StatementsNews
Fresenius Medical Care Names Shervin Korangy CEO
(RTTNews) - Fresenius Medical Care AG (FME.DE, FME) announced that Shervin J. Korangy will become Chief Executive Officer (CEO) and Chair of the Management Board, effective October 12, 2026. He will s...
Fresenius Medical Care AG (FMS) Shares Fall 7.7% -- What GF Score of 74 Tells Investors
Fresenius Medical Care AG (FMS) Shares Fall 7.7% -- What GF Score of 74 Tells Investors
Fresenius Medical Care (FMS) Names Shervin Korangy as New CEO and Chair
Fresenius Medical Care (FMS) Names Shervin Korangy as New CEO and Chair
Fresenius Medical trading resumes
11:10 EDT Fresenius Medical (FMS) trading resumes
Fresenius Medical names Shervin Korangy as next CEO
Fresenius Medical (FMS) announced that Shervin Korangy will become Chief Executive Officer and Chair of the Management Board, effective October 12. The supervisory board unanimously appointed Korangy ...
EQS-Adhoc: Fresenius Medical Care AG : Change in CEO – Shervin J. Korangy Succeeds Helen Giza
EQS-Ad-hoc: Fresenius Medical Care AG / Key word(s): Personnel decisions / Executive Board Fresenius Medical Care AG : Change in CEO – Shervin J. Korangy Succeeds Helen Giza 07-Oct-2026 / 16:54 CET/CE...
Fresenius Medical trading halted, news pending
10:37 EDT Fresenius Medical (FMS) trading halted, news pending
Fresenius Medical downgraded to Hold from Buy at Berenberg
Berenberg downgraded Fresenius Medical (FMS) to Hold from Buy with a price target of EUR 42, down from EUR 60, following a transfer of coverage. Evidence of positive U.S. kidney…
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expe...
Fresenius Medical Care AG (FMS) Stock Down 3.9% -- Now Undervalued? GF Score: 74/100
Fresenius Medical Care AG (FMS) Stock Down 3.9% -- Now Undervalued? GF Score: 74/100
EQS-PVR: Fresenius Medical Care AG: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG 10.09.2026 /...
Fresenius Medical Care Becomes Oversold (FMS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Fresenius Cuts Fresenius Medical Care Stake, Raises About €300 Mln
(RTTNews) - Fresenius SE & Co. KGaA (FRE.DE) announced that it has agreed to sell approximately 7.8 million shares in Fresenius Medical Care AG (FMS), representing about 2.9% of the dialysis company's...
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
EQS-CMS: Fresenius Medical Care AG : Release of a capital market information
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014 Fresenius Medical Care AG : Release of a capital marke...
Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript
U.S. referral execution gap offset by strong margin expansion and transformation savings.
Fresenius Medical price target raised to $25.80 from $25.50 at Bernstein
Bernstein analyst Susannah Ludwig raised the firm’s price target on Fresenius Medical (FMS) to $25.80 from $25.50 and keeps a Market Perform rating on the shares. The firm notes the…
Fresenius Medical price target lowered to EUR 32.30 from EUR 37.40 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Fresenius Medical (FMS) to EUR 32.30 from EUR 37.40 and keeps an Overweight rating on the shares. Published first on…
Fresenius Medical price target lowered to EUR 31 from EUR 32 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Fresenius Medical (FMS) to EUR 31 from EUR 32 and keeps an Underweight rating on the shares.
Fresenius Medical price target lowered to $25 from $26 at Truist
Truist lowered the firm’s price target on Fresenius Medical (FMS) to $25 from $26 and keeps a Hold rating on the shares.
Fresenius Medical Care AG Q2 Sales Increase
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius Medical Care AG (FME.DE) reported a profit for second quarter of EUR218 millionThe company's earnings totaled EUR218 million, or EUR0.81 per share. ...
Fresenius Medical Care AG (FMS) Shares Fall 5.0% -- What GF Score of 73 Tells Investors
Fresenius Medical Care AG (FMS) Shares Fall 5.0% -- What GF Score of 73 Tells Investors
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year out...